Galactose decorated PLGA nanoparticles for hepatic delivery of acyclovir

Drug Development and Industrial Pharmacy

Volumn 39, Issue 12, 2013, Pages 1866-1873

  Gupta, Swati ^a,b   Agarwal, Abhinav ^a   Gupta, Nishant Kumar ^a,c   Saraogi, Gauravkant ^a   Agrawal, Himanshu ^d   Agrawal, G P ^a  

^a DR H S GOUR UNIVERSITY   (India)

^b AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

^c Arjuna Natural Extracts Ltd   (India)

^d M S UNIVERSITY OF BARODA   (India)

Author keywords

Acyclovir; Galactose; Hepatic delivery; Nanoparticles; PLGA; Targeting

Indexed keywords

ACICLOVIR; GALACTOSE; NANOPARTICLE; POLYGLACTIN;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TARGETING; FLUORESCENCE MICROSCOPY; HEMOLYSIS; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; LIVER; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; FEMALE; GALACTOSE; GLYCOLATES; HEMOLYSIS; LACTIC ACID; LIVER; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 84887252361     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.662510     Document Type: Article

References (38)

1. Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL et al.; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/ Cancer-Hepatitis B Virus Study Group. (2007). Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol, 5:921-931.
2. Lavanchy D. (2004). Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat, 11:97-107. (Pubitemid 38365759)
3. McMahon BJ, Holck P, Bulkow L, Snowball M. (2001). Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med, 135:759-768. (Pubitemid 33051260)
4. Ganem D, Prince AM. (2004). Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med, 350:1118-1129. (Pubitemid 38298992)
5. Davoodian P, Dadvand H, Mahoori K, Amoozandeh A, Salavati A. (2009). Prevalence of selected sexually and blood-borne infections in Injecting drug abuser inmates of bandar abbas and roodan correction facilities, Iran, 2002. Braz J Infect Dis, 13:356-358.
6. Märker-Hermann E, Schütz N, Bauer H. (2010). [Viral arthritides]. Z Rheumatol, 69:871-878.
7. Zhang YL, Pan HY, Chen CR, Lou GQ, Ye RX, Lu DR. (2008). [The roles of saliva testing for preventing hepatitis B virus spreading]. Zhonghua Yu Fang Yi Xue Za Zhi, 42:596-598.
8. Sanjay S, Huang P, Lavanya R. (2011). Herpes zoster ophthalmicus. Curr Treat Options Neurol, 13:79-91.
9. Lolis MS, González L, Cohen PJ, Schwartz RA. (2008). Drugresistant herpes simplex virus in HIV infected patients. Acta Dermatovenerol Croat, 16:204-208.
10. Jones CA, Walker KS, Badawi N. (2009). Antiviral agents for treatment of herpes simplex virus infection in neonates. Cochrane Database Syst Rev, 8:CD004206.
11. Hostetler KY, Beadle JR, Hornbuckle WE, Bellezza CA, Tochkov IA, Cote PJ et al. (2000). Antiviral activities of oral 1-Ohexadecylpropanediol-3- phosphoacyclovir and acyclovir in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother, 44:1964-1969. (Pubitemid 30422956)
12. Kern ER, Palmer J, Szczech G, Painter G, Hostetler KY. (2000). Efficacy of topical acyclovir monophosphate, acyclovir, or penciclovir in orofacial HSV-1 infections of mice and genital HSV-2 infections of guinea pigs. Nucleosides Nucleotides Nucleic Acids, 19:501-513. (Pubitemid 30230057)
13. Haefeli WE, Schoenenberger RA, Weiss P, Ritz RF. (1993). Acyclovirinduced neurotoxicity: concentration-side effect relationship in acyclovir overdose. Am J Med, 94:212-215. (Pubitemid 23046448)
14. Stulzera HK, Tagliarib MP, ParizeaAL, Silvab MAS, Laranjeiraa MCM. (2008). Evaluation of cross-linked chitosan microparticles containing acyclovir obtained by spray-drying. Mater Sci Eng C, 29:387-392.
15. Saraogi GK, Gupta P, Gupta UD, Jain NK, Agrawal GP. (2010). Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharm, 385:143-149.
16. Nahar M, Mishra D, Dubey V, Jain NK. (2008). Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles. Nanomedicine, 4:252-261.
17. Rolland JP, Maynor BW, Euliss LE, Exner AE, Denison GM, DeSimone JM. (2005). Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J Am Chem Soc, 127:10096-10100. (Pubitemid 40995455)
18. Jain PK, ElSayed IH, El-Sayed MA. (2007). Au nanoparticles target cancer. Nano Today, 2:18-29. (Pubitemid 46196541)
19. Li Y, Wei P, Li J, Li L. (2011). Pharmacokinetic analysis and optimization of hydroxycamptothecin-loaded nanoparticles for liver targeting. Drug Dev Ind Pharm, (In Press).
20. Andersson LI, Hellman P, Eriksson H. (2008). Receptor-mediated endocytosis of particles by peripheral dendritic cells. Hum Immunol, 69:625-633.
21. Tanaka T, Shiramoto S, Miyashita M, Fujishima Y, Kaneo Y. (2004). Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int J Pharm, 277:39-61. (Pubitemid 38670420)
22. Klose D, Siepmann F, Elkharraz K, Siepmann J. (2008). PLGAbased drug delivery systems: importance of the type of drug and device geometry. Int J Pharm, 354:95-103. (Pubitemid 351410450)
23. Wang Y, Jiang G, Qiu T, Ding F. (2011). Preparation and evaluation of paclitaxel-loaded nanoparticle incorporated with galactosecarrying polymer for hepatocyte targeted delivery. Drug Dev Ind Pharm, doi:10.3109/03639045.2011. 637052.
24. Okuno K, Nakamura K, Tanaka A, Yachi K, Yasutomi M. (1998). Hepatic immunopotentiation by galactose-entrapped liposomal IL-2 compound in the treatment of liver metastases. Surg Today, 28:64-69. (Pubitemid 28069393)
25. Kohgo Y, Kato J, Nakaya R, Mogi Y, Yago H, Sakai Y et al. (1993). Production and characterization of specific asialoglycoprotein receptor antibodies. Hybridoma, 12:591-598. (Pubitemid 24198150)
26. Fiume L, Di Stefano G, Busi C, Mattioli A, Bonino F, Torrani-Cerenzia M et al. (1997). Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor. J Viral Hepat, 4:363-370. (Pubitemid 127733496)
27. Morille M, Passirani C, Letrou-Bonneval E, Benoit JP, Pitard B. (2009). Galactosylated DNA lipid nanocapsules for efficient hepatocyte targeting. Int J Pharm, 379:293-300.
28. Wang SN, Deng YH, Xu H, Wu HB, Qiu YK, Chen DW. (2006). Synthesis of a novel galactosylated lipid and its application to the hepatocyte-selective targeting of liposomal doxorubicin. Eur J Pharm Biopharm, 62:32-38. (Pubitemid 41736022)
29. Akamatsu K, Yamasaki Y, Nishikawa M, Takakura Y, Hashida M. (1999). Development of a hepatocyte-specific prostaglandin E(1) polymeric prodrug and its potential for preventing carbon tetrachloride-induced fulminant hepatitis in mice. J Pharmacol Exp Ther, 290:1242-1249. (Pubitemid 29400266)
30. Mitchell JP, Roberts KD, Langley J, Koentgen F, Lambert JN. (1999). A direct method for the formation of peptide and carbohydrate dendrimers. Bioorg Med Chem Lett, 9:2785-2788. (Pubitemid 29481162)
31. Tewes F, Munnier E, Antoon B, NgaboniOkassa L, Cohen-Jonathan S, Marchais H et al. (2007). Comparative study of doxorubicinloaded poly(lactide-co- glycolide) nanoparticles prepared by single and double emulsion methods. Eur J Pharm Biopharm, 66:488-492. (Pubitemid 46756231)
32. Bahrami G, Mirzaeei Sh, Kiani A. (2005). Determination of acyclovir in human serum by high-performance liquid chromatography using liquid-liquid extraction and its application in pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci, 816:327-331.
33. Nimje N, Agarwal A, Saraogi GK, Lariya N, Rai G, Agrawal H et al. (2009). Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J Drug Target, 17:777-787.
34. Yadav AK, Agarwal A, Rai G, Mishra P, Jain S, Mishra AK et al. (2010). Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil. Drug Deliv, 17:561-572.
35. Tu J, Zhong S, Li P. (2004). Studies on acyclovir-dextran conjugate: synthesis and pharmacokinetics. Drug Dev Ind Pharm, 30:959-965. (Pubitemid 39453047)
36. Jain A, Agarwal A, Majumder S, Lariya N, Khaya A, Agrawal H et al. (2010). Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release, 148:359-367.
37. Agarwal A, Gupta U, Asthana A, Jain NK. (2009). Dextran conjugated dendritic nanoconstructs as potential vectors for anticancer agent. Biomaterials, 30:3588-3596.
38. Jain SK, Gupta Y, Jain A, Saxena AR, Khare P, Jain A. (2008). Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomedicine, 4:41-48. (Pubitemid 351324205)